3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
8
Other hematologic neoplasm
4
Dermatologic
2
Sarcoma
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
361
Leukemia, Myeloid, Acute
302
Myeloproliferative Disorders
155
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
142
Precursor Cell Lymphoblastic Leukemia-Lymphoma
115
Primary Myelofibrosis
103
Leukemia, Myelomonocytic, Chronic
89
Lymphoma, Non-Hodgkin
76
Leukemia
71
Polycythemia Vera
64
Multiple Myeloma
55
Hodgkin Disease
50
Hematologic Neoplasms
49
Leukemia, Lymphocytic, Chronic, B-Cell
44
Leukemia, Biphenotypic, Acute
41
Thrombocythemia, Essential
40
Lymphoma
40
Myelodysplastic-Myeloproliferative Diseases
32
Neoplasms
29
Leukemia, Myeloid, Chronic-Phase
28
Anemia, Refractory, with Excess of Blasts
24
Recurrence
23
Anemia, Aplastic
21
Lymphoma, Mantle-Cell
20
Lymphoma, Follicular
20
Hematologic Diseases
20
Burkitt Lymphoma
20
Blastic Plasmacytoid Dendritic Cell Neoplasm
20
Blast Crisis
20
Histiocytosis, Langerhans-Cell
19
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Myeloid
×
1 year
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled